Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.0414 EUR
−359.51 M EUR
158.49 M EUR
292.67 M
About Iovance Biotherapeutics, Inc.
Sector
Industry
CEO
Frederick G. Vogt
Website
Headquarters
San Carlos
Founded
2007
ISIN
US4622601007
FIGI
BBG01TNY3SD6
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Frequently Asked Questions
The current price of 1IOVA is 1.9000 EUR — it has increased by 5.86% in the past 24 hours. Watch Iovance Biotherapeutics Inc stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange Iovance Biotherapeutics Inc stocks are traded under the ticker 1IOVA.
1IOVA stock has risen by 25.41% compared to the previous week, the month change is a −5.35% fall, over the last year Iovance Biotherapeutics Inc has showed a −34.00% decrease.
We've gathered analysts' opinions on Iovance Biotherapeutics Inc future price: according to them, 1IOVA price has a max estimate of 17.24 EUR and a min estimate of 0.86 EUR. Watch 1IOVA chart and read a more detailed Iovance Biotherapeutics Inc stock forecast: see what analysts think of Iovance Biotherapeutics Inc and suggest that you do with its stocks.
1IOVA reached its all-time high on Aug 11, 2025 with the price of 18.7880 EUR, and its all-time low was 1.1034 EUR and was reached on Sep 30, 2025. View more price dynamics on 1IOVA chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
1IOVA stock is 9.75% volatile and has beta coefficient of 1.58. Track Iovance Biotherapeutics Inc stock price on the chart and check out the list of the most volatile stocks — is Iovance Biotherapeutics Inc there?
Today Iovance Biotherapeutics Inc has the market capitalization of 723.51 M, it has increased by 0.87% over the last week.
Yes, you can track Iovance Biotherapeutics Inc financials in yearly and quarterly reports right on TradingView.
Iovance Biotherapeutics Inc is going to release the next earnings report on Nov 6, 2025. Keep track of upcoming events with our Earnings Calendar.
1IOVA earnings for the last quarter are −0.28 EUR per share, whereas the estimation was −0.24 EUR resulting in a −16.70% surprise. The estimated earnings for the next quarter are −0.21 EUR per share. See more details about Iovance Biotherapeutics Inc earnings.
Iovance Biotherapeutics Inc revenue for the last quarter amounts to 50.89 M EUR, despite the estimated figure of 56.96 M EUR. In the next quarter, revenue is expected to reach 64.00 M EUR.
1IOVA net income for the last quarter is −94.79 M EUR, while the quarter before that showed −107.37 M EUR of net income which accounts for 11.72% change. Track more Iovance Biotherapeutics Inc financial stats to get the full picture.
No, 1IOVA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 22, 2025, the company has 838 employees. See our rating of the largest employees — is Iovance Biotherapeutics Inc on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Iovance Biotherapeutics Inc EBITDA is −309.68 M EUR, and current EBITDA margin is −214.34%. See more stats in Iovance Biotherapeutics Inc financial statements.
Like other stocks, 1IOVA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Iovance Biotherapeutics Inc stock right from TradingView charts — choose your broker and connect to your account.